4.3 Article

2013 White Paper on recent issues in bioanalysis: 'hybrid' - the best of LBA and LCMS

期刊

BIOANALYSIS
卷 5, 期 23, 页码 2903-2918

出版社

FUTURE SCI LTD
DOI: 10.4155/bio.13.238

关键词

-

资金

  1. US FDA
  2. Europe EMA
  3. Health Canada
  4. Netherlands MEB
  5. Brazil ANVISA
  6. Japan MHLW
  7. UK MHRA

向作者/读者索取更多资源

The 2013 7th Workshop on Recent Issues in Bioanalysis was held in Long Beach, California, USA, where close to 500 professionals from pharmaceutical and biopharmaceutical companies, CROs and regulatory agencies convened to discuss current topics of interest in bioanalysis. These hot' topics, which covered both small and large molecules, were the starting point for fruitful exchanges of knowledge, and sharing of ideas among speakers, panelists and attendees. The discussions led to specific recommendations pertinent to bioanalytical science. Such as the previous editions, this 2013 White Paper addresses important bioanalytical issues and provides practical answers to the topics presented, discussed and agreed upon by the global bioanalytical community attending the 7th Workshop on Recent Issues in Bioanalysis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemical Research Methods

Bead-extraction and heat-dissociation (BEHD): A novel way to overcome drug and matrix interference in immunogenicity testing

Weifeng Xu, Michael Sank, Jennifer Cummings, Stephen Carl, Marina Juhel, Carol Gleason, Robert Dodge, Binodh S. DeSilva, Gerry Kolaitis, Renuka Pillutla

JOURNAL OF IMMUNOLOGICAL METHODS (2018)

Editorial Material Pharmacology & Pharmacy

The Journey to AAPS 2020: a Reflection from Strategic Planning to PharmSci 360

Joseph W. Polli, Christopher R. McCurdy, Dale Eric Wurster, Binodh S. DeSilva, Annette Bak, Reina Bendayan, Bernd Meibohm, Allen C. Templeton, William Weiser

AAPS JOURNAL (2019)

Editorial Material Pharmacology & Pharmacy

The Journey to AAPS 2020: a Reflection from Strategic Planning to PharmSci 360

Joseph W. Polli, Christopher R. McCurdy, Dale Eric Wurster, Binodh S. DeSilva, Annette Bak, Reina Bendayan, Bernd Meibohm, Allen C. Templeton, William Weiser

AAPS PHARMSCITECH (2018)

Article Chemistry, Medicinal

Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of Anemia

Ping Liu, Liping Wang, Byron G. DuBois, Vincent J. Colandrea, Rongqiang Liu, Jiaqiang Cai, Xiaoxing Du, Weiro Quan, William Morris, Jianwu Bai, Bimjhana Bishwokarma, Mangeng Cheng, Jennifer Piesvaux, Kallol Ray, Carla Alpert, Chi-Sung Chiu, Mark Zielstorff, Joseph M. Metzger, Liming Yang, Dennis Leung, Candice Alleyne, Stella H. Vincent, Vincenzo Pucci, Xiaofang Li, Alejandro Crespo, Dominique Stickens, Jeffrey J. Hale, Feroze Ujjainwalla, Christopher J. Sinz

ACS MEDICINAL CHEMISTRY LETTERS (2018)

Article Pharmacology & Pharmacy

Report on the AAPS Immunogenicity Guidance Forum

Heather Myler, Boris Gorovits, Kelli Phillips, Viswanath Devanarayan, Adrienne Clements-Egan, George R. Gunn, Susan Kirshner, Binodh DeSilva, Vinod P. Shah

AAPS JOURNAL (2019)

Article Pharmacology & Pharmacy

Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1

Lora Hamuro, Giridhar S. Tirucherai, Sean M. Crawford, Akbar Nayeem, Renuka C. Pillutla, Binodh S. DeSilva, Tarek A. Leil, Craig J. Thalhauser

AAPS JOURNAL (2019)

Article Oncology

Fumarate Metabolic Signature for the Detection of Reed Syndrome in Humans

Ruth T. Casey, Mary A. McLean, Benjamin G. Challis, Terri P. McVeigh, Anne Y. Warren, Lee Mendil, Richard Houghton, Stefano De Sanctis, Vasilis Kosmoliaptsis, Richard N. Sandford, Ferdia A. Gallagher, Eamonn R. Maher

CLINICAL CANCER RESEARCH (2020)

Article Multidisciplinary Sciences

Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer

Hemant M. Kocher, Bristi Basu, Fieke E. M. Froeling, Debashis Sarker, Sarah Slater, Dominic Carlin, Nandita M. deSouza, Katja N. De Paepe, Michelle R. Goulart, Christine Hughes, Ahmet Imrali, Rhiannon Roberts, Maria Pawula, Richard Houghton, Cheryl Lawrence, Yathushan Yogeswaran, Kelly Mousa, Carike Coetzee, Peter Sasieni, Aaron Prendergast, David J. Propper

NATURE COMMUNICATIONS (2020)

Review Biochemical Research Methods

Evaluation of homogeneous proximity immunoassays for preclinical bioanalysis

Padmanabhan Eangoor, Sharmistha Das, Vincenzo Pucci

BIOANALYSIS (2020)

Article Chemistry, Multidisciplinary

Divinylpyrimidine reagents generate antibody-drug conjugates with excellent in vivo efficacy and tolerability

Stephen J. Walsh, Soleilmane Omarjee, Friederike M. Dannheim, Dominique-Laurent Couturier, Dorentina Bexheti, Lee Mendil, Gemma Cronshaw, Toby Fewster, Charlotte Gregg, Cara Brodie, Jodi L. Miller, Richard Houghton, Jason S. Carroll, David R. Spring

Summary: The development of divinylpyrimidine (DVP) reagents for the synthesis of antibody-drug conjugates (ADCs) with in vivo efficacy and tolerability is reported. Detailed structural characterization of the synthesized ADCs was first conducted, followed by in vitro and in vivo evaluation of the ADCs' ability to safely and selectively eradicate target-positive tumors.

CHEMICAL COMMUNICATIONS (2022)

Article Oncology

STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors

Samanthi A. Perera, Johnny E. Kopinja, Yanhong Ma, Eric S. Muise, Jason Laskey, Kalyan Chakravarthy, Yiping Chen, Long Cui, Jeremy Presland, Manjiri Sathe, Sarah Javaid, Ellen C. Minnihan, Heidi M. Ferguson, Jennifer Piesvaux, Bo-Sheng Pan, Shuxia Zhao, Sharad K. Sharma, Hyun Chong Woo, Vincenzo Pucci, Ian Knemeyer, Saso Cemerski, Jared Cumming, B. Wesley Trotter, Archie Tse, Anuradha Khilnani, Sheila Ranganath, Brian J. Long, David Jonathan Bennett, George H. Addona

Summary: STING agonists can enhance anti-PD-1 immune profile, promote tumor control, and have potential therapeutic value for patients with aggressive tumors.

MOLECULAR CANCER THERAPEUTICS (2022)

Review Pharmacology & Pharmacy

Subcutaneous catabolism of peptide therapeutics: bioanalytical approaches and ADME considerations

Simone Esposito, Laura Orsatti, Vincenzo Pucci

Summary: This review discusses the evolution of technology and strategy in elucidating peptide subcutaneous catabolism. Modern bioanalytical technologies and bioinformatics platforms have enabled in silico, in vitro, and in vivo tools for characterising peptide catabolism and guiding the design of peptides with improved subcutaneous bioavailability. More predictive models are desired to improve the correlation between subcutaneous catabolism and other factors driving subcutaneous absorption.

XENOBIOTICA (2022)

Article Chemistry, Medicinal

Discovery of a Novel Series of Imidazopyrazine Derivatives as Potent SHP2 Allosteric Inhibitors

Esther Torrente, Valentina Fodale, Alina Ciammaichella, Federica Ferrigno, Jesus M. Ontoria, Simona Ponzi, Ilaria Rossetti, Alessio Sferrazza, Jerome Amaudrut, Antonino Missineo, Simone Esposito, Simone Palombo, Martina Nibbio, Mauro Cerretani, Monica Bisbocci, Antonella Cellucci, Annalise di Marco, Cristina Alli, Vincenzo Pucci, Carlo Toniatti, Alessia Petrocchi

Summary: Protein tyrosine phosphatase SHP2 acts as an oncogenic protein by regulating various cytokine receptors and receptor tyrosine kinase signaling pathways. Here, we present a new series of SHP2 allosteric inhibitors with an imidazopyrazine 6,5-fused heterocyclic system as the central scaffold, which exhibit strong enzymatic and cellular potency. Compound 8, a highly potent SHP2 allosteric inhibitor, was identified through structure-activity relationship studies, showing novel stabilizing interactions compared to known SHP2 inhibitors. Further optimization led to the discovery of analogue 10, which demonstrates excellent potency and promising pharmacokinetic properties in rodents.

ACS MEDICINAL CHEMISTRY LETTERS (2023)

Article Chemistry, Medicinal

Discovery of a Novel Series of Imidazopyrazine Derivatives as Potent SHP2 Allosteric Inhibitors

Esther Torrente, Valentina Fodale, Alina Ciammaichella, Federica Ferrigno, Jesus M. Ontoria, Simona Ponzi, Ilaria Rossetti, Alessio Sferrazza, Jerome Amaudrut, Antonino Missineo, Simone Esposito, Simone Palombo, Martina Nibbio, Mauro Cerretani, Monica Bisbocci, Antonella Cellucci, Annalise di Marco, Cristina Alli, Vincenzo Pucci, Carlo Toniatti, Alessia Petrocchi

Summary: Protein tyrosine phosphatase SHP2 is an oncogenic protein that regulates multiple signaling pathways. This study identified a new series of SHP2 allosteric inhibitors with a central scaffold of imidazopyrazine 6,5-fused heterocyclic system, showing good potency in enzyme and cellular assays. Compound 8, a highly potent SHP2 allosteric inhibitor, was identified through SAR studies and X-ray analyses revealed novel stabilizing interactions. Further optimization led to the discovery of analogue 10, which exhibits excellent potency and promising pharmacokinetic profile in rodents.

ACS MEDICINAL CHEMISTRY LETTERS (2023)

Article Oncology

Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells

Yun Wang, Long Cui, Peter Georgiev, Latika Singh, Yanyan Zheng, Ying Yu, Jeff Grein, Chunsheng Zhang, Eric S. Muise, David L. Sloman, Heidi Ferguson, Hongshi Yu, Cristina St. Pierre, Pranal J. Dakle, Vincenzo Pucci, James Baker, Andrey Loboda, Doug Linn, Christopher Brynczka, Doug Wilson, Brian B. Haines, Brian Long, Richard Wnek, Svetlana Sadekova, Michael Rosenzweig, Andrew Haidle, Yongxin Han, Sheila H. Ranganath

Summary: The study demonstrates that the EP4 inhibitor MF-766 synergizes with anti-PD-1 therapy to enhance anti-tumor activity by modulating infiltration profiles of myeloid cells, NK cells, cDCs, and T-cells in the tumor microenvironment (TME).

ONCOIMMUNOLOGY (2021)

暂无数据